Gene

EGF

epidermal growth factor

Explore in graph →CI-GENE-00044362HGNC:3229 ENSG00000138798 NCBI 1950 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGF EXPRESSION1
Cetuximab	Head and Neck Squamous Cell Carcinoma	Predictive	D	Supports Resistance	3	accepted	EID826 3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amp… (full text at CIViC) PMID 25677871 · Ansell et al., 2016 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (7)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved7 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 2012) cellline_ccle_broad	unmapped	Ssm	115	1,020	11.3%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
· J Oral Pathol Med · 2016 · PMID 25677871 · validated civic_curation pubmed